ARON AID survey

This survey is designed to gather insights on the availability and reimbursement status of treatments for renal cell carcinoma, urothelial carcinoma, and prostate cancer across different countries. The purpose is to evaluate the accessibility of various therapies for patients and understand the healthcare system’s approach to supporting advanced and adjuvant cancer treatments.

The survey collects general information, including the respondent’s country, contact details, and discipline (Oncology, Urology, Radiotherapy, or Nuclear Medicine). It also categorizes treatment availability into three levels: totally reimbursed by the public healthcare system, partially reimbursed by the public healthcare system, and available only through private insurance.

For each Country, the first 6 Colleagues who will complete the survey will be included as co-authors in the three publications that we’ll submit

ARON AID survey

ARON AID survey

Personal Informations

Renal cell carcinoma

Adjuvant Setting

SUNITINIB (S-TRACK):

PEMBROLIZUMAB: (KEYNOTE-564):

Advanced disease

SUNITINIB:

SORAFENIB:

EVEROLIMUS:

PAZOPANIB:

CABOZANTINIB:

TIVOZANIB:

AXITINIB:

BEVACIZUMAB:

NIVOLUMAB:

EVEROLIMUS + LENVATINIB:

AXITINIB + AVELUMAB:

AXITINIB + PEMBROLIZUMAB:

AXITINIB + TORIPALIMAB:

NIVOLUMAB + IPILIMUMAB:

NIVOLUMAB + CABOZANTINIB:

PEMBROLIZUMAB + LENVATINIB:

BELZUTIFAN (FROM SECOND-LINE):

BELZUTIFAN (VHL DISEASE):

Urothelial Carcinoma

BCG unresponsive or intolerant PEMBROLIZUMAB:

Adjuvant Setting NIVOLUMAB:

Advanced disease PEMBROLIZUMAB (FIRST-LINE CISPLATIN UNFIT):

ATEZOLIZUMAB: (FIRST-LINE CISPLATIN UNFIT)

PEMBROLIZUMAB + ENFORTUMAB (FIRST LINE CISPlATIN UNFIT):

PEMBROLIZUMAB + ENFORTUMAB (FIRST LINE CISPlATIN FIT) :

NIVOLUMAB + CISPLATIN + GEM: (FIRST-LINE THERAPY)

AVELUMAB: (MAINTAINANCE THERAPY)

PEMBROLIZUMAB: (SECOND OR FURTHER LINE THERAPY)

ATEZOLIZUMAB: (SECOND OR FURTHER LINE THERAPY)

NIVOLUMAB: (SECOND OR FURTHER LINE THERAPY)

AVELUMAB: (SECOND OR FURTHER LINE THERAPY)

ENFORTUMAB VEDOTIN:

ERDAFINTINIB (SECOND OR FURTHER LINE THERAPY) :

SACITUZUMAB GOVITECAN: (SECOND OR FURTHER LINE THERAPY)

Prostate Cancer

Advanced disease (non-metastatic HSPC with biochemical recurrence)

ENZALUTAMIDE

Advanced disease (mHSPC)

DOCETAXEL:

ABIRATERONE ACETATE:

APALUTAMIDE:

ENZALUTAMIDE:

DAROLUTAMIDE

DAROLUTAMIDE + DOCETAXEL

ABIRATERONE ACETATE + DOCETAXEL:

Advanced disease (non-metastatic CRPC)

APALUTAMIDE:

ENZALUTAMIDE:

DAROLUTAMIDE:

Advanced Disease (mCRPC)

ABIRATERONE ACETATE:

ENZALUTAMIDE:

DOCETAXEL:

CABAZITAXEL:

CABAZITAXEL + CARBOPLATIN:

RADIUM-223:

LUTETIUM-177:

SIPULEUCEL-T:

OLAPARIB:

RUCAPARIB:

ABIRATERONE ACETATE + OLAPARIB:

ABIRATERONE ACETATE + NIRAPARIB:

ENZANLUTAMIDE + TALAZOPARIB:

PEMBROLIZUMAB (FOR MSI-HIGH):

Do you want to join us ?